Trials / Unknown
UnknownNCT03291002
Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC
Phase I Study of Intratumoral CV8102 in Patients With Advanced Melanoma, Squamous Cell Carcinoma of the Skin, Squamous Cell Carcinoma of the Head and Neck, or Adenoid Cystic Carcinoma
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 98 (actual)
- Sponsor
- CureVac · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma. Patients will receive CV8102 as single agent or in combination with SoC anti-PD-1 therapy.
Conditions
- Melanoma (Skin)
- Squamous Cell Carcinoma of the Skin
- Carcinoma, Squamous Cell of Head and Neck
- Carcinoma, Adenoid Cystic
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CV8102 | CV8102 alone |
| BIOLOGICAL | CV8102 + anti-PD-1 therapy | CV8102 in combination with standard of care anti-PD-1 therapy |
Timeline
- Start date
- 2017-09-25
- Primary completion
- 2022-10-01
- Completion
- 2023-02-01
- First posted
- 2017-09-25
- Last updated
- 2021-11-04
Locations
22 sites across 5 countries: Austria, France, Germany, Russia, Spain
Source: ClinicalTrials.gov record NCT03291002. Inclusion in this directory is not an endorsement.